Literature DB >> 36216946

Endpoints and estimands: understanding trials of weight-loss drugs.

Amanda I Adler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36216946     DOI： 10.1038/s41591-022-02032-6

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   87.241


× No keyword cloud information.
  1 in total

1.  Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.

Authors:  W Timothy Garvey; Rachel L Batterham; Meena Bhatta; Silvio Buscemi; Louise N Christensen; Juan P Frias; Esteban Jódar; Kristian Kandler; Georgia Rigas; Thomas A Wadden; Sean Wharton
Journal:  Nat Med       Date:  2022-10-10       Impact factor: 87.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.